220 publications

Name Date Type Actions

Q1 2023 Sales: €145M

Vetoquinol recorded sales of €145 million for the first three months of the 2023 financial year, up 7.7% on a reported basis and 7.2% at constant exchange rates.

 		20/04/2023 Public releases

Availability of the 2022 universal registration document

On 13 April 2023, Vetoquinol filed its 2022 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format).

 		13/04/2023 Public releases

A visionary strategy

The key steps of a visionary strategy

 		03/04/2023 Press releases communication

2022 ANNUAL RESULTS

Annual sales: €540m (up 3.6% as reported)
Essentials sales: €304m (up 4.5% as reported)
EBIT before depreciation of acquired assets: €99m (18.3% of sales)
Net income - Group share: €48m (8.9% of sales)
EBITDA: €118m (21.9% of sales)
Free cash-flow: €63m

 		23/03/2023 Public releases

Serving animal Health - 90 years

Serving animal Health for over 90 years

 		06/03/2023 Press releases communication

Buyback programs - February 2023

Monthly communication regarding buyback programs

 		06/03/2023 Description of buyback programs

Buyback programs - January 2023

Monthly communication regarding buyback programs 

 		07/02/2023 Description of buyback programs

In 2023 Vetoquinol celebrates its 90th anniversary. - 90 years

The story of an incredible family saga. From a regional pharmaceutical laboratory to a world leader in animal health.

 		31/01/2023 Press releases communication

Annual sales 2022

Total group Sales: €540 million (up 3.6% as reported)
Annual Sales of Essential products: €304 million (up 4.5% as reported)

 		18/01/2023 Public releases

Buyback programs - december 2022 Monthly communication regarding buyback programs

04/01/2023 Description of buyback programs